Physician profile
Evan Levine
NPI 1326482555
$80,296.83
in general payments reported to CMS, 2019-2025
16 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $304 · 2021: $624 · 2023: $170 · 2024: $164 · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Travel and Lodging: $5,800 · Food and Beverage: $1,999 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,385.94 |
| Travel and Lodging | $5,800.15 |
| Food and Beverage | $1,998.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $78,533.78 | 2025 | Wegovy |
| Amgen INC. | $769.61 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.32 | 2020-2021 | |
| Pfizer INC. | $198.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $139.87 | 2021 | |
| Lilly USA, LLC | $73.12 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Bridgebio Pharma, INC. | $69.20 | 2025 | Attruby |
| Amarin Pharma, INC. | $54.18 | 2021 | |
| Scpharmaceuticals INC. | $52.52 | 2025 | |
| Novartis Pharmaceuticals Corporation | $44.32 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $40.34 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $32.85 | 2020-2021 | |
| Portola Pharmaceuticals, LLC | $27.09 | 2020 | |
| Abbott Laboratories | $19.16 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.57 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.